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Abstract
Adult T-cell leukemia/lymphoma (ATL) carries a poor prognosis even in indolent subtypes. We performed targeted deep
sequencing combined with mapping of HTLV-1 proviral integration sites of 61 ATL patients of African and Caribbean
origin. This revealed mutations mainly affecting TCR/NF-kB (74%), T-cell trafficking (46%), immune escape (29%), and
cell cycle (26%) related pathways, consistent with the genomic landscape previously reported in a large Japanese cohort. To
examine the evolution of mutational signatures upon disease progression while tracking the viral integration architecture of
the malignant clone, we carried out a longitudinal study of patients who either relapsed or progressed from an indolent to an
aggressive subtype. Serial analysis of relapsing patients identified several patterns of clonal evolution. In progressing
patients, the longitudinal study revealed NF-kB/NFAT mutations at progression that were present at a subclonal level at
diagnosis (allelic frequency < 5%). Moreover, the presence in indolent subtypes of mutations affecting the TCR/NF-kB
pathway, whether clonal or subclonal, was associated with significantly shorter time to progression and overall survival. Our
observations reveal the clonal dynamics of ATL mutational signatures at relapse and during progression. Our study defines a
new subgroup of indolent ATLs characterized by a mutational signature at high risk of transformation.
Introduction
Adult T-cell leukemia/lymphoma (ATL) is a rare mature T-
cell malignancy associated with human T-cell leukemia-1
(HTLV-1) infection. The Southwestern region of Japan,
Sub-Saharan Africa, South America, and the Caribbean area
are the main endemic regions [1]. HTLV-1 infection mainly
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occurs during childhood and only ~5% of infected indivi-
duals will develop ATL following a long latency period [2].
Four subtypes are described: two indolent (smoldering and
chronic) and two aggressive (acute and lymphoma) forms
[3]. The prognosis is poor, especially in aggressive subtypes
with a median overall survival (OS) of <1 year despite
intensive treatments including allogeneic stem cell trans-
plantation [4, 5]. Indolent forms also carry a relatively
adverse outcome with a median OS of 36 and 56 months for
chronic and smoldering subtypes, respectively, mainly
related to their evolution toward an aggressive subtype
[4, 6]. As a consequence, the identification of indolent
patients at high risk of progression toward an advanced
disease remains a major challenge in the management of
ATL patients.
The characterization of the landscape of genetic abnorm-
alities in a Japanese ATL cohort revealed the presence of
recurrent somatic mutations and copy number variants,
especially in three main pathways: TCR/NF-kB signaling, T-
cell trafficking, and immune escape mechanisms [7]. How-
ever, little is known as regards the dynamics of genomic
alterations in patients who relapse or progress from an
indolent subtype to an aggressive form of the disease.
The very poor outcome of aggressive but also indolent
subtypes stresses the urgent need for new therapeutic
approaches and tools to better understanding mechanisms
governing relapse as well as identifying patients with indo-
lent subtypes who are at risk of transformation toward an
aggressive form. To this end, much effort has been devoted
to identifying such patients. Previous studies have identified
a subgroup of the indolent subtype called “unfavorable
chronic” using routine biological variables associated with
decreased progression-free survival (PFS) and decreased OS
[8]. From a molecular point of view, two studies have
highlighted the negative impact of CDKN2A deletions and
TP53 mutations [9–11]. More recently, the correlation of
genomic alterations described by the Japanese consortium
with corresponding clinical data reinforced the hypothesis
that the profile of oncogenic changes, such as IRF4 muta-
tions, CDKN2A deletion, and PDL-1 amplification, is asso-
ciated with a shorter PFS and OS in indolent forms [12].
Here, we describe the genomic landscape of 61 ATL
cases of Afro-Caribbean origin based on targeted deep
sequencing (TDS) combined with genome-wide mapping of
proviral integration sites. We explore the evolution of
mutational signatures in two distinct sets of longitudinal
samples. This revealed viral and mutational profile patterns
specific of relapse. Furthermore, our study identifies clonal
and subclonal mutational profiles that define an indolent
ATL subgroup at high risk of transformation. Our study
provides novel insights into the genetic basis of ATL, the
molecular dynamics of relapse and progression, and
proposes a new prognosis classification scheme for indolent




The study had a retrospective observational design. Sixty-one
patients with an ATL at diagnosis were analyzed. Diagnosis
of ATL was based on clinical and biological features
including immunophenotyping, the presence of HTLV-1-
specific antibodies, and the detection of HTLV-1 proviral
DNA. Serial samples were available for 15 patients. These
longitudinal cohort consisted of one sample collected at
diagnosis and either a second or several samples corre-
sponding to progression to an indolent to an aggressive
(disease progression, i.e., from chronic to acute), or to a
relapse after a period of complete clinical remission according
to previously published response criteria [8]. This study was
approved by the ethical committee (CPP Ile de France II,
CNIL: number 1692254, registration number 000001072) and
all surviving patients gave written informed consent.
Nucleic acid extraction
DNA and RNA extractions were performed on frozen per-
ipheral blood mononuclear cells (PBMC) or frozen tumor
tissue using the “all PREP DNA/RNA mini kit” (Qiagen) or
“DNA Blood and Tissue kit” (Qiagen) according to the
manufacturer’s instructions.
Targeted deep sequencing (TDS)
TDS was applied to genomic DNA extracted from 61 ATL
samples at diagnosis and 28 additional serial samples. A
first approach consisted of a custom capture-based next
generation sequencing (NGS) panel representing 80 genes
relevant to hematological malignancies. A TruSeq
Amplicon-based NGS panel of 36 genes was then designed
and further used to confirm the genes most frequently
affected in our cohort (Supplementary Tables 1, 2a, b). To
this confirmatory panel, we added 19 genes that were
recently shown altered with a frequency of ≥3% of the cases
in the Japanese ATL cohort [7]. In total, 99 genes were
sequenced. Libraries were prepared according to Illumina
instructions and sequenced on a Miseq instrument (ILLU-
MINA, 500× with mean coverage 95% for the capture panel
and 2000× with mean coverage 90% for the TruSeq panel).
The TruSeq panel allowed the detection of mutations at
a subclonal level defined by variant allele frequency
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(VAF) <5%. Clonal and subclonal mutations were thus
defined as mutations with VAF >5% and <5%, respectively.
Sequences were aligned to the human reference genome
hg19 using BWA. Downstream processing was carried out
with the Genome Analysis Toolkit (GATK), SAMtools, and
Picard, following documented best practices. Variant calls
were made with the GATK Unified Genotyper. The anno-
tation process was based on the latest release of the
Ensemble number version GRCch37 database. Variants
were annotated and analyzed using the Polyweb software
interface designed by the Bioinformatics platform of the
University Paris Descartes. Prioritization of the variants was
performed using the same interface. Relevant somatic
mutations were called and filtered by excluding synon-
ymous SNVs and known variants listed in SNP databases
(dbSNP131, 1000 Genomes Project, 5000 Exomes project).
All variants showing <5 alterative reads were excluded. All
other variants were manually checked and kept if they were
found either in the COSMIC database or estimated to be
relevant according to the Polyphen score, which was used to
estimate the impact of the mutation on protein structure or
function [13]. Sequencing data are deposited in the Eur-
opean Genome-Phenome Archive (www.ebi.ac.uk/ega),
under accession number EGAS00001004483.
Evaluation of duplication and large deletion events
with TDS
In order to evaluate duplication and large deletion events,
we assessed the copy numbers of each targeted region in a
given individual. For each individual, the relative read
counts for each targeted region was determined as the ratio
of the read count for that region divided by the total abso-
lute read counts of all targeted regions of the design. The
ratio of the relative read count of a region in a given indi-
vidual over the average relative read counts in other indi-
viduals of the run resulted in the estimated copy number for
that region in that individual.
SNP array karyotyping
Genome-wide copy number analysis was performed on
32 samples (27 samples at diagnosis and 5 samples at
progression/relapse) using the Affymetrix CYTOSCAN HD
and the Illumina HUMAN-OMNIEXPRESS according to
the manufacturers’ instructions. Details are available in
Supplementary methods.
Next generation sequencing (NGS) genome-wide
mapping of HTLV-1 integration sites
To map HTLV-1 integration sites and measure the abun-
dance of the corresponding clones, DNA extracted from
PBMCs of ATL patients was sheared and processed as
described [14, 15]. Briefly, sheared DNA fragments were
selectively end-repaired and A-tailed by Taq polymerase
mediated linear extension from LTR-specific primers
located in both the 5′ and 3′ LTR. Biotinylated dTTPs were
incorporated during this extension step. Adapters con-
taining UMIs were ligated to the A overhangs and strep-
tavidin bead-mediated selection was carried out, followed
by PCR amplification using off-the-shelf Nextera indexes
to enable multiplexing. Libraries were sequenced on a
MiSeq instrument (kit V2, 2 × 150 bp). Removal of
PCR duplicates combining UMI, shear site, and genomic
integration site information ensured accurate esti-
mation of clone abundance. HTLV-1 genomic integration
information are deposited in the Retroviral Integration
Database [16].
Quantification of HTLV-1 proviral load and RNA
sequencing
HTLV-1 proviral loads and ATL transcriptomes were
examined as previously reported [14, 15, 17]. Details are
available in Supplementary methods.
Statistical analysis
The end-points studied were OS and PFS. Progression was
defined as disease progression to an aggressive subtype for
patients with an indolent subtype who achieved partial
response (PR) or remained in stable disease (SD). OS and
PFS curves were estimated using Kaplan–Meier product-
limit estimator. Data were censored at time of allogeneic
stem cell transplantation. All analyses were carried out
using the R software.
Fish plot
For clonal evolution, variants were filtered based on
sequencing depth (>20 reads of total depth and >10 reads
for alternative reads) and further filtered by excluding
synonymous SNV, UTR, and intronic, and if listed as SNPs
in public databases (Supplementary Table 3). Fish plots and
clonality charts were generated in R using SciClone, Clo-
nEvol, and Fish plot packages [18, 19].
Results
Genomic landscape of ATL
Sixty-one cases of ATL at diagnosis were analyzed by TDS.
The median age at diagnosis was 51 years (range 17–73
years). Among them, 15 presented an indolent (smoldering
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or chronic) and 46 had an aggressive (39 acute and 8
lymphoma) subtypes (Supplementary Table 4).
A total of 248 clonal somatic mutations (defined as
mutations showing a VAF > 5%, Methods) in 48 genes were
identified including missense (n= 137), nonsense (n= 61),
splice (n= 17), frameshift (n= 26), non-frameshift inser-
tion/deletion (n= 5), or phase (n= 2) mutations. Mutations
were detected in 57 patients (92%) with a median of three
mutations per patient (range 0–10). The most commonly
mutated genes were CCR4 (n= 23, 38%), PLCG1 (n= 18,
29%), PRKCB (n= 13, 21%), CARD11 (n= 13, 21%),
TBL1XR1 (n= 11, 18%), TP53 (n= 11, 18%), FAS (n=
10, 16%), GATA3 (n= 10, 16%), NOTCH1 (n= 9, 15%),
CSNK2B (n= 9, 15%), STAT3 (n= 8, 13%), RHOA (n= 7,
12%), and VAV1 (n= 7, 12%) (Figs. 1a, 2, Supplementary
Table 5). Forty-five (74%) patient samples harbored gene
deletions, which were confirmed by SNP array analysis in
27 cases with available material (Supplementary Fig. 1).
The most commonly deleted genes were CDKN2A (n= 22,
36%), ATXN1 (n= 13, 21%), HLA-B (n= 11, 18%), and
TP53 (n= 10, 17%). Nine patients (15%) showed two
mutations in the same gene: CCR4 (n= 3), PLCG1 (3),
CARD11 (n= 1), HNRNPA2B1 (n= 1), TBL1XR1 (n= 1),
and HLA-B (n= 1). Ten patients had mutations in one allele
and a deletion in the other allele. Genes affected by such bi-
allelic inactivation were TP53 (n= 5), HLA-B (1), CD58
(n= 1), FAS (n= 1), RB1 (n= 1), and GPR-183 (n= 1).
Genomic alterations were clustered in four main path-
ways. Forty-five (74%) patients carried mutations affecting
the TCR/NF-kB pathway (CD28, PLCG1, CARD11,
PRKCB, CBLB, IRF4, CSNK1A1, FYN, RHOA, and VAV1),
among which 31 (51%) affecting the restricted NF-kB/
NFAT pathway (PLCG1, CARD11, PRKCB, and IRF4)
[7, 20]. Twenty-eight (46%) ATLs harbored mutations
affecting the T-cell trafficking pathway (CCR4, CCR7, and
GP183). Eighteen (29%) ATLs showed mutations affecting
genes involved in immune escape (FAS, HLA-B, B2M, and
CD58). Sixteen (26%) patients showed mutations in genes
involved in cell cycle regulation (TP53, POT1, and RB1). In
addition, 31 (51%) patients showed mutations in genes
involved in regulation of transcription and/or epigenetic
regulation and 13 (21%) in the JAK/STAT signaling path-
way. The mutational landscape identified in our study is
consistent with the ATL mutational profiles described in the
previously published Japanese study (Fig. 1b, c). In addi-
tion, we did not observe differences between African (n=
26) and Caribbean (n= 22) descend in terms of genomic
landscape. However, we observed a high rate of mutations
in the cell cycle pathway in the “Guyana” subgroup (6/7)
mainly due to a high number of mutations in the TP53
locus. These results should be interpreted with caution due
to the small number of patients in the Guyana subgroup
(Supplementary Table S4 and Supplementary Fig. 2).
Indolent and aggressive subtypes differ in their
mutational profiles
The average number of mutations per sample at diagnosis
was significantly higher in aggressive subtypes than in
indolent forms (5 versus 2, p= 0.000084, Fig. 3a, b). This
mainly resulted from a higher number of genomic altera-
tions in genes involved in the TCR/NF-kB pathway. More
specifically, 40/46 (87%) patients with an aggressive sub-
type showed at least one activating mutation in this pathway
compared with 5/15 (33%) in indolent ATLs (p= 0.00015).
This higher rate of mutations may be biased by the over-
representation of genes belonging to the TCR/NF-kB
pathway in our TDS panel (n= 10). However, the differ-
ence was also significant when comparing the proportion of
activating mutations in the restricted NF-kB/NFAT path-
way: 28/46 (61%) versus 3/15 (27%) (p= 0.00776),
while in other highlighted pathways with similar gene
numbers in the panel—immune escape (n= 4), cell cycle
regulation (n= 3), T-cell trafficking (n= 3)—it was not
(Fig. 3c, p= ns).
Genomic landscape and proviral integration
architecture in ATLs at relapse
In order to explore the potential contribution of the temporal
acquisition of driver mutations at relapse, we analyzed
seven patients (ATLs 1, 11, 44, 60, 100, 105, and 110) who
achieved complete remission but relapsed after a median
time of 32.9 months (range 6.2–75.7 months) (Fig. 4 and
Supplementary Table 6). With the exception of two patients
(ATLs 11 and 110) who showed a viral clone switch
between diagnosis and relapse (a viral clone being defined
as a sub-population of cells carrying the HTLV-1 provirus
at the same position in the genome), all other cases (n= 5)
showed the same dominant viral malignant clone at diag-
nosis and relapse, with a similar relative abundance of the
corresponding clones. Viral RNA-seq data were also
examined for ATLs 1, 44, 60, and 100 at both time points.
This confirmed that HTLV-1 transcriptional profiles did not
significantly differ between diagnosis and relapse, with
consistent production of the viral antisense transcripts HBZ
and absence of robust HTLV-1-dependent transcription
from the positive strand (Supplementary Fig. 3) [14, 15].
Acquisition of de novo mutations in ATLs at relapse
In relapsing patients who showed an identical viral
malignant clone at diagnosis and relapse (n= 5), the
median number of mutations at diagnosis was 4 (range
3–7). As expected, we identified additional mutations at
relapse. Among these de novo mutations, we mainly
found genes affecting the TCR/NF-kB pathway and
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immune escape mechanisms (Fig. 5a, b and Supplemen-
tary Fig. 3a). More specifically, three cases acquired
activating mutations in the NF-kB/NFAT pathway at
relapse: ATLs 44, 60, and 105 showed mutations in IRF4,
PRKCB, and PLCG1 loci, respectively. Three cases
acquired loss of function mutations in HLA-B, a gene
affecting immune-surveillance (ATLs 1, 44, and 100). In
two patients (ATLs 44 and 60), some of the mutations
Fig. 1 Mutational landscape of ATL. a Distribution of clonal
somatic mutations in 61 ATL cases classified according to the affected
signaling pathway. Mutational profiles obtained by targeted sequen-
cing of 99 genes in 61 ATLs including 8 lymphoma (black), 38 acute
(dark gray), 13 chronic (gray), and 2 smoldering (light gray) subtypes.
Four cases did not show clonal mutations. Clonal mutations are
defined as mutations with a VAF >5% and are ordered according to the
signaling pathway they affect. Mutation hierarchization was performed
according to previously published studies [7, 20]. The mutation
PLCG1 R48W was not considered as a TCR/NF-kB pathway dama-
ging mutation [20]. b Frequency of main mutated genes in our ATL
cohort (61 cases) and patients from the Japanese ATL analyzed by
targeted exome sequencing (370 cases) [7]. c Frequency of main
pathways affected by mutations in our ATL cohort and patients from
the Japanese ATL cohort analyzed by targeted exome sequencing.
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Fig. 2 Mapping of variants identified in genes belonging to the NF-
kB/NFAT pathway and coding for GTPase proteins. Distribution of
clonal (VAF > 5%) mutations found in 41/61 diagnostic samples in
main mutated genes belonging to the TCR/NF-kB pathway: PLCG1,
PRKCB, CARD11 and IRF4 (NF-kB/NFAT pathway) and VAV1 and
RHOA (GTPase proteins). Nonsense mutations are marked in grey,
missense in blue grey, frameshift in turquoise, non-frameshift in red
and splicing in orange.
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identified at diagnosis were no longer identified at relapse.
Interestingly, the acquisition of these de novo mutations
emerged in a new distinct subclone within the founding
clone. This new subclone, not detectable at diagnosis
outcompeted the accompanying subclones after induction
therapy. More specifically, in ATL 44 and ATL 60, the
original major subclone had been eradicated (Fig. 5a and
Supplementary Fig. 4a), while in ATL 100 and ATL 105
it persisted at similar frequency (Fig. 5b and Supple-
mentary Fig. 4a).
Viral clone switch is not a rare event in the course
of ATL
In addition to two above-mentioned cases that were
characterized by a viral clone switch at relapse (ATLs 11
and 110), a third ATL patient with an indolent subtype
showed a viral clone switch at progression (ATL 6). This
patient developed a lymphoma subtype while being
treated for an indolent form of the disease. For all three
cases, as expected, the mutational pattern was different
Fig. 4 Scaled schematic timeline of ATL cases examined in long-
itudinal studies. The line diagrams summarize sample collection time
points for each longitudinally studied ATL patient. The top panel
shows patients (n= 7) who achieved CR after first-line therapy and
relapsed. The bottom panel represents patients with an indolent
subtype (n= 14) who were managed with various therapeutic
approaches and who obtained PR or remained in SD. Among them,
nine patients progressed to an aggressive subtype (acute or lymphoma)
and five remained in PR or SD until the last follow-up.
Fig. 3 Aggressive ATL subtypes carry a higher number of muta-
tions. a Frequency of each mutation among indolent and aggressive
subtypes. b Number of mutations observed per ATL sample in indo-
lent and aggressive subtypes. c Number of ATL cases with somatic
mutations affecting genes belonging to the main mutated pathways in
indolent (light gray) and aggressive (dark gray) subtypes, respectively.
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between diagnosis and relapse, in line with the emergence
of a novel clone. The new malignant clone identified at
relapse consistently carried an inactivating mutation in
the TP53 locus and additional mutations such as altera-
tions affecting immune escape mechanisms (ATLs 11 and
110), the Notch 1 pathway (ATL 6), and the TCR/NF-kB
pathway (ATL 110) (Fig. 5c, d and Supplementary
Fig. 4b).
Genomic architecture of longitudinal samples
reveals subclonal mutations in indolent subtypes
We then analyzed indolent subtypes, and more specifically
those (n= 9) who progressed to an aggressive disease
(Fig. 4, Supplementary Fig. 5, Supplementary Table 6).
Three of these ATLs were also examined by RNA-seq and
CGH array (ATLs 2, 4, and 37).
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Patients were managed with different therapeutic
approaches including ZIDOVUDINE-INTERFERON ther-
apy and watch and wait strategy (Supplementary Table 6).
Of the 14/15 patients who achieved PR or showed SD, nine
progressed to an aggressive subtype with a median pro-
gression time of 25 months (range 3.6–42.1 months), while
five patients remained in PR or SD until the last follow-up
(median follow-up 32 months).
With the exception of ATL 6 who showed a viral clone
switch at progression, all cases retained the same viral
malignant clone with a similar relative abundance between
sequential paired samples. The viral transcriptional profiles
did not show significant differences between time points.
Like for ATL samples at relapse, we did not observe robust
transcription from the positive strand while antisense tran-
scripts were consistently produced, in agreement with pre-
vious observations [7, 14].
Genomic profiling of ATL samples at progression
revealed the acquisition of mutations in seven of the nine
patients examined. De novo mutations were identified in
two main pathways: NF-kB/NFAT (n= 4, ATLs 2, 4, 37,
and 102) and cell cycle (n= 3, ATLs 6, 9, and 23). Inter-
estingly, the novel clonal mutations affecting the NF-kB/
NFAT pathway at progression were identified at a subclonal
level in the matched indolent ATL samples (VAF < 5%,
range 0.7–5%) (Fig. 6a, b and Supplementary Figs. 6, 7).
We identified two mutations in the CARD11 locus (ATLs 2
and 102, hot spot D345E), one in the PLCG1 locus (ATL 4,
hot spot D1165H) and one in the PRKCB locus (ATL 37,
hot spot D427N). Analysis of dynamic evolution revealed a
strong enrichment of NF-kB/NFAT pathway-associated
mutations at progression, uncovering the clonal outgrowth
of a preexisting rare subclone present as a sub-population
embedded in the main tumor clone at the indolent stage
(Fig. 6a, b).
Finally, of the two patients who progressed without
TCR/NF-kB mutations, one progressed to a lymphoma
subtype with a viral clone switch (ATL 6, Fig. 5c) as pre-
viously mentioned, while the other (ATL 9) retained the
same dominant viral clone with additional mutations in
TP53 and FAS loci at progression (Supplementary Fig. 6).
These mutations were not identified at earlier time points
(diagnosis and 6 months before progression), even at a
subclonal level, suggesting their de novo acquisition.
Of note, we also verified that the increase in VAFs
observed upon ATL progression were effectively revealing
clonal or subclonal outgrowth rather than an overall
increase in the proportion of HTLV-1 infected cells. To this
end, we examined proviral loads of the corresponding
samples and found no significant difference between mat-
ched sample pairs.
Subclonal and clonal mutations have predictive
value in indolent subtypes
ATL patients with an indolent subtype and at least one
clonal or subclonal mutation in the TCR/NF-kB pathway
(n= 8) had a significantly shorter PFS compared with
patients who did not show mutations (n= 6) (median
20 months versus not reached, 2 year PFS 33% versus
100%, p= 0.0034) and a shorter OS (median 28.5 months
versus not reached; 3 year OS 40% versus 100%, p=
0.0005), suggesting these mutations are the dominant driver
of progression. At progression, the disease became refrac-
tory to any treatment and, with the exception of one patient
who received allogeneic stem cell transplantation, all
patients died shortly after progression (Fig. 6c).
Discussion
This study describes the mutational landscape of ATL in a
cohort of 61 patients mainly originating from Africa and the
Caribbean area, broadening the genomic characterization of
this heterogeneous disease to a distinct genetic background.
Our observations are in agreement with those reported in a
larger Japanese cohort of 426 ATLs [7]. We confirm the
significant proportion of genomic alterations in genes
Fig. 5 Evolution of somatic mutations and viral integration
architecture between diagnosis and relapse. Examples of mutational
evolution within the dominant viral malignant clone for four repre-
sentative ATL cases studied at diagnosis and relapse. Pie charts
represent the HTLV-1 proviral integration architecture of the corre-
sponding ATLs. Scatter graphs show mutations identified at diagnosis
(x-axis) and relapse (y-axis) with their corresponding VAF. Mutations
depicted in light green are specific of diagnosis. Mutations in dark
green are associated with relapse. Mutations in blue are shared
between diagnosis and relapse. Mutational evolution of four additional
ATLs examined are shown in Supplementary Fig. 3. a, b Diagnosis/
relapse sample pairs from two patients who relapsed with an identical
viral dominant clone. ATL 44 (a) and ATL 100 (b) show the same
single dominant proviral integration site (IS) with a relative abundance
of >90% at diagnosis and relapse, corresponding to the presumed
malignant clone. The fish plots illustrate models of mutational evo-
lution during the course of the disease. Damaging and non-damaging
mutations are represented in black bold and gray, respectively. The
remaining genes and the clones to which they are assigned are avail-
able in the supplement. In both cases, the founding clone (in gray)
observed in the primary tumor at diagnosis carries specific damaging
mutations. The major subclone represented in blue is either eradicated
(mutations in NRAS and IRF2BP2, ATL 44) or persists at a similar
frequency (mutations in CD58, IRF2BP2, and CSNK1A1, ATL 100) at
relapse. In both cases, a novel subclone (yellow) derived from the
founding clone emerges and expands, becoming the dominant sub-
clone at relapse. That clone acquired additional mutations (HLA-B,
IRF4, and IRF2BP2 for ATL 44, KRAS, ZFP36L2, and HLA-B for
ATL 100). Data from three additional patients available in Supple-
mentary Fig. 3a. c, d Diagnosis/relapse sample pairs from patients who
relapsed (ATL 11) or progressed (ATL 6) with a novel viral dominant
tumor clone (clone switch). Data from an additional patient available
in Supplementary Fig. 3b.
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coding for proteins involved in the TCR/NF-kB signaling
pathway, associated with T-cell trafficking and tumor
immune-evasion, but also cell cycle integrity. These results
support the conclusion that the patients’ genetic background
and environment do not have a significant impact on the
mutational landscape of ATL. Although there is
undisputable evidence that the virus plays a critical role in
the transformation process of HTLV-1-infected T-cells, we
observed a significant overlap between the ATL mutational
landscape and mutations reported in mature T- or B-cell
malignancies of nonviral etiology [20–23]. We also found
that compared with indolent forms, aggressive subtypes
Fig. 6 Evolution of subclonal and clonal somatic mutations in
indolent ATLs progressing toward an aggressive subtype. a, b
Longitudinal samples from two ATL patients with an initial indolent
subtype who progressed to an aggressive subtype (ATL 4 and ATL
37). Pie charts represent the proviral integration architecture. Both
ATLs show a single dominant viral insertion site corresponding to the
presumed malignant clone. Fish plots illustrate models of mutational
evolution. The founding clone is represented in gray. The subclone
that carried the mutation in the TCR/NF-kB pathway (PLCG1
locus for ATL 4, PRKCB locus for ATL 37) is represented in red.
Data from three additional patients available in Supplementary Fig. 6.
c Kaplan–Meier curve for progression-free survival (PFS) and overall
survival (OS) according to the presence of at least one activating
mutation of the TCR/NF-kB pathway at a clonal or subclonal level.
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carry a higher rate of clonal mutations mainly associated
with a higher proportion of mutations in the TCR/NF-kB
pathway including the NF-kB/NFAT pathway.
A recent study has reported the mutational landscape of a
smaller cohort of 30 ATL patients from Caribbean descend
[24]. The authors observed a higher rate of mutations in
genes implicated in epigenetic regulation such as EP300
(20%) and a lower rate in the TCR/NF-kB pathway com-
pared with the study published by the Japanese consortium.
A possible explanation of this discrepancy is the composi-
tion of the targeted NGS panels. More specifically, the
American and the Japanese panels only share 17 genes.
When comparing our cohort with the cohort of Shah et al.,
even if the panels shared 45 genes, only 16 of the genes
mutated in our panel were present in the American panel. In
addition, the American panel did not include most of the
main mutated genes identified in the Japanese cohort and
ours, notably those belonging to the TCR/NF-kB pathway
(PLCG1, PRKCB, and IRF4) and to the T-cell trafficking
(CCR4, which is mutated in 1/3 of the cases in our cohort).
Unlike previous genomic studies, we analyzed serial
samples of ATL patients to explore the dynamics of
mutational profiles observed at diagnosis and better under-
stand disease evolution. The longitudinal study revealed the
evolution of mutational signatures observed in the original
HTLV-1-infected malignant T-cell clone. HTLV-1 clonality
analysis indicated that the main insertion site identified at
diagnosis was retained upon progression or relapse in the
majority of the patients. This provided indirect evidence
that the mutational changes originated from the founding
malignant clone rather than a newly emerged tumor clone
with a different proviral integration site.
The observations in patients with aggressive subtypes
who relapsed with the same main viral insertion site sys-
tematically revealed changes in the genomic landscape of
the founding malignant clone through the acquisition of de
novo mutations. Additional mutations were clustered in two
main pathways: immune escape and NF-kB/NFAT path-
way. In addition, at relapse we observed clonal hetero-
geneity within the founding tumor clone with the
emergence of a novel dominant subclone that was not
identified at diagnosis and carried specific somatic muta-
tions, while the main subclone at diagnosis had been either
eradicated or maintained at comparable levels. Our obser-
vations in ATL are consistent with findings in acute mye-
loid leukemia (AML) [18, 19]. In agreement with earlier
reports [7], we consistently observed the absence of Tax
expression in ATLs whether at diagnosis, relapse, or upon
progression [14, 15]. This supports the conclusion that in
malignant T-cell, the acquisition of somatic mutations is
independent of Tax expression although the contribution of
viral products to early steps of T-cell transformation is
undeniable [25, 26]. We also observed three cases with a
viral clone switch at progression/relapse, which consistently
carried a mutation in the TP53 locus. Malignant transfor-
mation of a newly emerging tumor clone may be facilitated
by genomic instability promoted by therapeutic interven-
tion, in agreement with previous observations in myeloid
malignancies and clonal hematopoiesis [27, 28]. However,
the contribution to the malignant development of these
clones by the transient expression of the Tax oncoprotein
cannot be excluded [29].
Deep sequencing of patients with indolent ATL who
progressed to aggressive forms revealed genomic alterations
mainly in the TCR/NF-kB pathway. In contrast to patients
who relapsed, aggressive ATLs progressing from indolent
subtypes showed an enrichment in TCR/NF-kB-associated
mutations from rare preexisting subclones found within the
main original tumor clone at the indolent stage. These
subclonal mutations are clustered in genes belonging the
NF-kB/NFAT pathway (PLCG1, CARD11, and PRKCB)
and are known to cause a gain of function.
Mutational analysis suggests that, irrelevant of their
clonal or subclonal nature, mutations in at least one of four
genes associated with the TCR-NF-kB pathway (PLCG1,
CARD11, PRKCB, and VAV1) carry prognostic significance
for ATL patients with an indolent subtype. We found that
these patients experienced significantly shorter time to
progression and survival rates. The prognostic value of
subclonal mutations observed in ATL is consistent with
recent reports demonstrating the clinical relevance of TP53
subclonal mutations in chronic lymphoid leukemia and
AML [30–32]. Our findings reveal the prognostic impact of
low-frequency TCR/NF-kB-mutated subclones on the out-
come of ATL patients, suggesting that this phenomenon
occurs for the well-known TCR/NF-kB-driver pathway. We
envision that the characterization of the subclonal archi-
tecture and its dynamics in the evolution of the disease will
be relevant for the management of ATL patients. The
observation of subclonal outgrowth at ATL progression and
the prognostic value of the corresponding subclonal muta-
tions identified in our discovery cohort will require vali-
dation in a larger patient cohort. Previous findings from a
Japanese genomic study identified mutations in IRF4 and/or
amplification of PDL-1 and/or deletion of CDKN2A,
defining an unfavorable subgroup of indolent ATLs [12].
We suggest implementing this “classifier” with the four
genes identified in our study. Targeting this specific set of
mutations in an integrated NGS workflow may become a
common approach to assess ATL’ genomic alterations and
improve risk stratification for indolent ATLs.
In conclusion, our study describes the genomic landscape
of ATL in patients of Afro-Caribbean origin, revealing a
genomic architecture similar to that previously identified
in a Japanese cohort, ruling out the contribution of the
genetic background to HTLV-1-dependent tumorigenesis.
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Furthermore, our longitudinal study identifies clonal evo-
lution and dynamics as important and previously unappre-
ciated contributors to disease progression in relapsing and
progressing ATL patients from a mutational and a viral
point of view. A particularly significant observation is the
identification of mutations in the TCR/NF-kB pathway in
low-frequency subclones defining a new unfavorable sub-
group within the indolent subtype with a high risk of pro-
gression to an aggressive disease.
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